Our Bayesian prediction models using the pathway scores on a cell line’s drug sensitivity provided high prediction accuracies (median test-set AUC > 0.8 across all drugs and all cancers) and selected cancer-specific pathway signatures in predicting drug response, such as hormone receptor–breast,53 and TSC/mTOR–pancreas.54,55 Our training models using cell lines were used to predict patients’ drug response and validated with their known sensitivities. The gene discussed is NR4A1; the disease is cancer.